Y Intercept (Hong Kong) LTD Akero Therapeutics, Inc. Transaction History
Y Intercept (Hong Kong) LTD
- $3.83 Billion
- Q3 2025
A detailed history of Y Intercept (Hong Kong) LTD transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Y Intercept (Hong Kong) LTD holds 7,661 shares of AKRO stock, worth $415,532. This represents 0.01% of its overall portfolio holdings.
Number of Shares
7,661
Previous 39,002
80.36%
Holding current value
$415,532
Previous $2.08 Million
82.56%
% of portfolio
0.01%
Previous 0.06%
Shares
6 transactions
Others Institutions Holding AKRO
# of Institutions
299Shares Held
92.3MCall Options Held
1.72MPut Options Held
901K-
Janus Henderson Group PLC London, X06.74MShares$365 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$311 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$303 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$297 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$246 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.52B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...